Issue Date: September 24, 2007
AstraZeneca transferring production to China is a very poor move (C&EN, July 30, page 40). At a time when products coming from China are highly suspect for major quality defects, and when critical products such as pharmaceuticals are not being labeled with country of origin, most of us will be reluctant to trust AstraZeneca's pharmaceuticals. My family and I will avail ourselves of other companies' products whenever possible.
Peter R. Lantos
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society